ARTICLE | Company News
Neurocrine, Ciba-Geigy Ltd. deal
August 5, 1996 7:00 AM UTC
NBIX will receive a $3 million milestone payment from partner Ciba-Geigy for the initiation of a Phase I trial with NBI-5788, a peptide vaccine to treat multiple sclerosis. The trial will take place i...